Here are three stocks with buy rank and strong value characteristics for investors to consider today, May 22:
Universal Insurance Holdings, Inc. (UVE - Free Report) : This insurance holding company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing by 18.8% over the last 60 days.
Universal has a price-to-earnings ratio (P/E) of 8.40 compared with 12.70 for the industry. The company possesses a Value Scoreof A.
The Hanover Insurance Group, Inc. (THG - Free Report) : This insurance company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing by 9.6% over the last 60 days.
The Hanover Insurance has a price-to-earnings ratio (P/E) of 10.55 compared with 12.70 for the industry. The company possesses a Value Score of A.
Ategrity Specialty Insurance Company Holdings (ASIC - Free Report) : This insurance company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its next year earnings increasing 9.6% over the last 60 days.
Ategrity Specialty Insurance Company has a price-to-earnings ratio (P/E) of 10.67 compared with 10.70 for the industry. The company possesses a Value Score of B.
See the full list of top ranked stocks here.
Learn more about the Value score and how it is calculated here.
Here are three stocks with buy rank and strong income characteristics for investors to consider today, May 22:
Universal Insurance Holdings, Inc. (UVE - Free Report) : This insurance holding company witnessed the Zacks Consensus Estimate for its current year earnings increasing 18.8% the last 60 days.
This Zacks Rank #1 company has a dividend yield of 1.6%, compared with the industry average of 0.8%.
The Hanover Insurance Group, Inc. (THG - Free Report) : This insurance company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 9.6% the last 60 days.
This Zacks Rank #1 company has a dividend yield of 2%, compared with the industry average of 0.8%.
Texas Instruments Incorporated (TXN - Free Report) : This semiconductor company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 11.5% in the last 60 days.
This Zacks Rank #1 company has a dividend yield of 1.7%, compared with the industry average of 0.0%.
See the full list of top ranked stocks here.
Find more top income stocks with some of our great premium screens.
Hanover Insurance Group (THG - Free Report) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.
The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
As such, the Zacks rating upgrade for Hanover Insurance is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their bulk investment action then leads to price movement for the stock.
Fundamentally speaking, rising earnings estimates and the consequent rating upgrade for Hanover Insurance imply an improvement in the company's underlying business. Investors should show their appreciation for this improving business trend by pushing the stock higher.
Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for Hanover InsuranceThis insurance company is expected to earn $18.46 per share for the fiscal year ending December 2026, which represents no year-over-year change.
Analysts have been steadily raising their estimates for Hanover Insurance. Over the past three months, the Zacks Consensus Estimate for the company has increased 9.5%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Hanover Insurance to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
It has been about a month since the last earnings report for Hanover Insurance Group (THG - Free Report) . Shares have lost about 0.2% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Hanover Insurance due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Hanover Insurance Q1 Earnings Top Estimates on Lower Cat Losses
The Hanover Insurance posted first-quarter 2026 operating income of $5.25 per share, which rose 35.7% year over year and beat the Zacks Consensus Estimate of $4.14 by 26.8%.
Total revenues rose 6.1% year over year to $1.7 billion but missed the consensus mark of $1.72 billion by 1.2%. Results reflected firm pricing and improved underlying loss trends, helping drive a record operating return on equity of 20.3%.
THG Delivers Better Combined Ratio Despite Cat Losses
Underwriting profitability strengthened in the quarter, with the consolidated combined ratio improving to 91.7% from 94.1% a year ago.
Catastrophe losses were $98.9 million, adding 6.3 points to the combined ratio.
Excluding catastrophes, the combined ratio improved to 85.4%, supported by a 2.3-point year-over-year decline in the loss and loss adjustment expense ratio. The current accident year combined ratio, excluding catastrophes, was 87.0%, pointing to better core underwriting performance.
Net premiums written increased to $1,559.7 million from $1,510.8 million, aided by renewal pricing and disciplined growth across businesses.
The Hanover’s Core Commercial Segment Benefits From Rate Action
Core Commercial generated net premiums written of $630.4 million, up 4.3% from the prior-year quarter. Renewal price increases were 8.6%, while rate increases were 7.5%, reflecting continued emphasis on adequate pricing and targeted appetite across small commercial and middle-market accounts.
Profitability improved meaningfully as underwriting actions flowed through. The segment’s combined ratio was 96.6% versus 103.4% a year ago, with the total loss and LAE ratio improving to 63.9% from 70.0%. Prior-year favorable development, excluding catastrophes, was 0.3 points, and GAAP underwriting profit swung to $17.8 million from a loss of $20.0 million in the prior-year period.
Specialty net premiums written increased 2.3% year over year to $366.7 million. Renewal price increases were 4.6% and rate increases were 2.4%, indicating steady momentum while maintaining underwriting discipline across the segment’s marine, professional, and other specialty offerings.
The segment produced a combined ratio of 84.2%, an improvement from 87.7% in the prior-year quarter. A lower total loss and loss adjustment expense ratio of 47.8% (down from 50.7%) helped lift GAAP underwriting profit to $56.1 million from $41.2 million, while the expense ratio was 36.4% compared with 37.0% a year earlier.
The Hanover’s Personal Lines Segment Mixed as Pricing Stays Firm
Personal Lines net premiums written rose 2.7% year over year to $562.6 million. Renewal price increases were 8.4% and rate increases were 4.3%, underscoring continued pricing traction as the company works to improve profitability in auto and homeowners lines.
Even with that pricing support, results were more mixed. The segment’s combined ratio was 91.5% compared with 89.7% a year earlier, as catastrophe losses remained elevated for the book, with a current-year catastrophe loss ratio of 12.4% versus 5.8% in the prior-year quarter. The total loss and LAE ratio was 65.8% compared with 64.4% a year ago, and GAAP underwriting profit totaled $52.3 million, down from $61.7 million.
THG Balance Sheet Advances With Book Value Increase
Hanover ended the quarter with book value per share of $101.86, up 1% from Dec. 31, 2025.
The investment portfolio expanded, with total investments rising 4% to $10.80 billion as of March 31, 2026, including fixed maturities of $9.98 billion. The company also reduced leverage, with short-term debt falling to $50.1 million from $375.0 million and long-term debt declining to $793.7 million from $843.3 million.
As of March 31, 2026, the operating insurance company's statutory capital and surplus were $3.54 billion, up from $3.34 billion as of Dec. 31, 2025.
Capital Deployment
From the start of the year till April 28, 2026, THG repurchased about 0.6 million shares for $101 million, of which about 0.5 million were repurchased during the first quarter of 2026 for $87 million. The company has about $72 million of remaining capacity under its existing share repurchase program.
How Have Estimates Been Moving Since Then?It turns out, fresh estimates have trended upward during the past month.
The consensus estimate has shifted 6.99% due to these changes.
VGM ScoresCurrently, Hanover Insurance has a average Growth Score of C, a score with the same score on the momentum front. However, the stock has a grade of A on the value side, putting it in the top 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Hanover Insurance has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.
, /PRNewswire/ -- The Hanover Insurance Group, Inc. (NYSE: THG) announced today its board of directors has declared a quarterly dividend of $0.95 per share on the issued and outstanding common stock of the company, payable June 26, 2026, to shareholders of record at the close of business on June 12, 2026.
Forward-Looking Statements
Statements regarding quarterly or future dividends, whether regular or special, payable to the company's shareholders, which may be subject to future increases, decreases, or elimination, as determined by The Hanover's board of directors, are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. The company cautions investors that any such forward-looking statements are not guarantees of future performance, including but not limited to, growth, earnings improvement, returns, future dividend payments, or the amount of such payments. Investors are directed to consider the risks and uncertainties in the company's business that may cause actual results to differ and/or affect the board's decision to declare dividends in the future, including those risks which are discussed in readily available documents, such as the company's annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other documents filed by The Hanover with the Securities and Exchange Commission and which are also available on hanover.com under "Investors."
About The Hanover
The Hanover Insurance Group, Inc. is the holding company for several property and casualty insurance companies, which together constitute one of the largest insurance businesses in the United States. The company provides exceptional insurance solutions through a select group of independent agents and brokers. Together with its agent partners, The Hanover offers standard and specialized insurance protection for small and mid-sized businesses, as well as for homes, automobiles, and other personal items. For more information, please visit hanover.com.
The Hanover's new survey highlights uncertainty around homeowners insurance coverage
, /PRNewswire/ -- 90% of homeowners¹ expressed concern about protecting their homes and personal property, but many don't know what their homeowners insurance protection covers, according to a new survey conducted by The Harris Poll on behalf of The Hanover Insurance Group, Inc. (NYSE: THG).
The Hanover's 2026 Home Report: The Coverage Confidence Gap shows that many homeowners buy insurance protection without checking to see what their policy covers. For example, many homeowners haven't verified that the following valued protections are part of their standard policy or require an additional purchase:
Identity fraud protection (helps cover costs to restore identity after fraud or identity theft) — 46% have not verified Service line coverage (repair or replacement of underground utility lines on a property, such as water or sewer lines) — 41% have not verified Water backup coverage (for damage to property caused by backed-up drains or sump pump overflow, not to be confused with flood insurance) — 38% have not verified Personal property replacement cost (replaces items with new equivalents at current prices) — 24% have not verified These coverages are not always automatically included in insurance quotes and can vary by carrier or policy tier.
The findings come at a time when homeowners report broad concern about protecting their homes and personal property. Homeowners cite regular repair costs (45%), damage from severe weather or natural disasters (42%), and non‑weather‑related events such as water leaks and fires (32%) as top concerns.
At the same time, the survey shows that homeowners prioritize comprehensive protection when choosing an insurance carrier and evaluating trade-offs between protection and price:
81% say comprehensive protection, with no coverage gaps or surprises, is absolutely essential or very important 74% say they would prefer a policy with broader protection, even if it costs more, over a homeowners insurance policy that provides fewer protections but costs less Together, the findings point to a gap between homeowners' preference for comprehensive protection and their confidence in what their policies provide.
"For many people, a home is their most important asset. Homeowners want confidence their insurance will protect them when it matters most, yet many aren't fully certain what their policies include," said Daniel C. Halsey, president of personal lines at The Hanover. "While price will always be a factor, choosing coverage based on cost alone can leave people under-protected and facing higher out-of-pocket expenses after a loss. Talking with an independent insurance agent can help homeowners understand their coverage, identify potential gaps and make more confident decisions about protecting their homes and financial well‑being."
To read the full 2026 Home Report: The Coverage Confidence Gap and learn more about home protection, please visit hanover.com.
About The Hanover
The Hanover Insurance Group, Inc. is the holding company for several property and casualty insurance companies, which together constitute one of the largest insurance businesses in the United States. The company provides exceptional insurance solutions through a select group of independent agents and brokers. Together with its agent partners, The Hanover offers standard and specialized insurance protection for small and mid-sized businesses, as well as for homes, automobiles, and other personal items. For more information, please visit hanover.com.
CONTACTS:
¹ For the purposes of this report, homeowners refer to those individuals who own a house.
Survey method
This survey was conducted online within the United States by The Harris Poll on behalf of The Hanover from March 5-9, 2026 among 1,173 adults ages 18 and older who own a house. The sampling precision of Harris online polls is measured by using a Bayesian credible interval. For this study, the sample data is accurate to within +/- 3.6 percentage points using a 95% confidence level.
For complete survey methodology, including weighting variables and subgroup sample sizes, please contact [email protected].
This material is provided for informational purposes only and does not provide any coverage or guarantee prevention of loss. All products are underwritten by The Hanover Insurance Company or one of its insurance company subsidiaries or affiliates ("The Hanover"). Coverage may not be available in all jurisdictions and is subject to the company underwriting guidelines and the issued policy. This material is provided for informational purposes only and does not provide any coverage. (For more information visit www.hanover.com.)
Key Takeaways THG maintains pricing above loss trends, helping support underwriting margins across segments.The Hanover expects Specialty growth to accelerate, led by Marine and technology investments.THG repurchased about $101M of stock as net investment income climbed 19.6% in Q1. Shares of The Hanover Insurance Group, Inc. (THG - Free Report) have gained 8.5% in the past year against the industry decline of 4.8%, while underperforming the Finance sector and the Zacks S&P 500 composite’s growth of 13.6% and 31.6%, respectively.
Disciplined underwriting, effective Pricing, specialty insurance expansion and rising investment income are likely driving the stock. The momentum can continue if pricing remains favorable and claims trends stay under control, though catastrophe losses, competitive pricing pressure and social inflation remain key risks.
Image Source: Zacks Investment Research
Some other insurers, like American Financial Group, Inc. (AFG - Free Report) and Mercury General Corporation (MCY - Free Report) , have risen 4.5% and 51.3%, respectively, in the past year. Meanwhile, shares of Arch Capital Group Ltd. (ACGL - Free Report) have lost 6.6% in the past year.
THG Shares Are ExpensiveIts shares are trading at a premium to the Zacks Property and Casualty Insurance industry. Its price-to-book value of 1.83X is higher than the industry average of 1.35X.
Image Source: Zacks Investment Research
THG’s Growth ProjectionThe Zacks Consensus Estimate for 2026 and 2027 revenues implies a year-over-year improvement of 4.7% and 4.8%, respectively.
The estimate for 2026 and 2027 earnings per share indicates a decrease of 3.8% and 0.3%, respectively.
Analysts' Opinion on THG Moves SouthThe consensus estimate for 2026 and 2027 earnings has moved 0.5% and 0.1% south, respectively, in the past 30 days.
THG’s Favorable Return on CapitalReturn on equity (ROE) for the trailing-12 months was 17.8%, compared favorably with the industry’s 6%. This reflects its efficiency in utilizing shareholders’ funds.
Return on invested capital in the trailing-12 months was 12.5%, better than the industry average of 5.7%, reflecting THG’s efficiency in utilizing funds to generate income.
THG’s Average Target Price Suggests UpsideBased on short-term price targets offered by eight analysts, the Zacks average price target is $206.38 per share. The average suggests a potential 10.8% upside from the last closing price.
Key Points to Note for THGThe Hanover’s pricing remains above loss trends across commercial and personal lines, supporting durable underwriting margins even as property markets soften. Management continues to expect pricing to rise in 2026 in commercial and personal auto liability, and retention has remained steady in commercial lines. With balanced net premiums written growth of 3.2% in first-quarter 2026, pricing discipline should keep underlying margins resilient even if growth stays measured.
Specialty continued to deliver attractive underwriting margins in first-quarter 2026. Management expects overall Specialty growth to ramp up, with Marine expected to return to upper single-digit growth for the rest of 2026. Technology investments, including AI-enabled triage and workflow modernization, are intended to improve speed to answer and mix quality, supporting Specialty’s role as a stabilizer as property competition evolves.
Personal Lines is benefiting from earned pricing and margin initiatives. As geographic diversification and full-account strategies scale, the segment has room to contribute steadier earnings and support consolidated results through the cycle.
Management continues to reinvest at higher yields than maturities, supporting growing investment. This has strengthened the company's investment portfolio returns and provided an additional source of earnings growth beyond underwriting operations.
THG remains committed to returning capital to shareholders through a combination of dividends and share repurchases.
ConclusionTHG is positioned to deliver steady earnings growth through premium rate increases, sustained pricing above trend, specialty strength and rising investment income. The company's diversified commercial and personal lines portfolio and ongoing share repurchases provide additional support for earnings and shareholder returns.
Coupled with premium expansion, strong underwriting discipline and higher return on capital, the time appears right for potential investors to bet on this Zacks Rank #1 (Strong Buy) insurer. You can see the complete list of today’s Zacks #1 Rank stocks here.
The new Quant Growth & Income Portfolio targets both capital appreciation and dividend yield. QG&I's diversified holdings include Exxon (XOM), EPR Properties (EPR), and Hanover Insurance Group (THG), each selected for strong value, growth, profitability, momentum, and EPS revisions.
Here are three stocks with buy rank and strong value characteristics for investors to consider today, June 9:
The Hanover Insurance Group, Inc. (THG - Free Report) : This insurance company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing by 9.5% over the last 60 days.
The Hanover Insurance Group has a price-to-earnings ratio (P/E) of 10.52 compared with 23.13 for the S&P. The company possesses a Value Scoreof A.
DaVita Inc. (DVA - Free Report) : This kidney dialysis company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing by 6.4% over the last 60 days.
DaVita has a price-to-earnings ratio (P/E) of 12.75 compared with 25.80 for the industry. The company possesses a Value Score of A.
Douglas Dynamics, Inc. (PLOW - Free Report) : This commercial vehicle solutions company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its next year earnings increasing 15.4% over the last 60 days.
Douglas Dynamics has a price-to-earnings ratio (P/E) of 15.17 compared with 23.13 for the S&P. The company possesses a Value Score of B.
See the full list of top ranked stocks here.
Learn more about the Value score and how it is calculated here.
Here are three stocks with buy rank and strong income characteristics for investors to consider today, June 9:
Douglas Dynamics, Inc. (PLOW - Free Report) : This commercial vehicle solutions company witnessed the Zacks Consensus Estimate for its current year earnings increasing 15.4% the last 60 days.
This Zacks Rank #1 company has a dividend yield of 2.7%, compared with the industry average of 0.0%.
Texas Instruments Incorporated (TXN - Free Report) : This semiconductor company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 20.6% the last 60 days.
This Zacks Rank #1 company has a dividend yield of 2.0%, compared with the industry average of 0.2%.
The Hanover Insurance Group, Inc. (THG - Free Report) : This insurance company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 9.5% in the last 60 days.
This Zacks Rank #1 company has a dividend yield of 2.0%, compared with the industry average of 0.8%.
See the full list of top ranked stocks here.
Find more top income stocks with some of our great premium screens.
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:
Douglas Dynamics, Inc. (PLOW - Free Report) : This commercial vehicle solutions company has seen the Zacks Consensus Estimate for its current year earnings increasing 15.4% over the last 60 days.
Texas Instruments Incorporated (TXN - Free Report) : This semiconductor company has seen the Zacks Consensus Estimate for its current year earnings increasing 20.6% over the last 60 days.
The Hanover Insurance Group, Inc. (THG - Free Report) : This insurance company has seen the Zacks Consensus Estimate for its current year earnings increasing 9.5% over the last 60 days.
Unisys Corporation (UIS - Free Report) : This technology services company has seen the Zacks Consensus Estimate for its current year earnings increasing 14.8% over the last 60 days.
EZCORP, Inc. (EZPW - Free Report) : This pawn services company has seen the Zacks Consensus Estimate for its current year earnings increasing 11.1% over the last 60 days.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.
One stock to keep an eye on is The Hanover Insurance Group (THG - Free Report) . THG is currently sporting a Zacks Rank #1 (Strong Buy), as well as a Value grade of A. The stock holds a P/E ratio of 10.86, while its industry has an average P/E of 26.25. THG's Forward P/E has been as high as 13.52 and as low as 10.12, with a median of 11.25, all within the past year.
Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. THG has a P/S ratio of 1. This compares to its industry's average P/S of 1.19.
These are only a few of the key metrics included in The Hanover Insurance Group's strong Value grade, but they help show that the stock is likely undervalued right now. When factoring in the strength of its earnings outlook, THG looks like an impressive value stock at the moment.
Combination pairs OLAPLEX’s premium hair care brand with Henkel’s global reach and resources
Transaction is expected to accelerate OLAPLEX’s value creation and expand access to premium, science-led hair-health solutions for stylists and consumers
OLAPLEX stockholders to receive $2.06 per share
NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- Olaplex Holdings, Inc. (“OLAPLEX” or “the Company”) (NASDAQ: OLPX), a premium hair care brand powered by science-led innovation and the professional hairstylist, today announced that it has entered into a definitive agreement to be acquired by Henkel AG & Co. KGaA (“Henkel”), a leading global manufacturer of well-known consumer and industrial brands, for $2.06 per share in a cash transaction, representing an equity value of approximately $1.4 billion. The transaction represents a premium of approximately 55% over OLAPLEX’s closing stock price on 3/25/2026 and a premium of approximately 45% over the volume weighted average price (VWAP) of OLAPLEX’s shares for the 30 trading days ended 3/25/2026.
Upon completion of the transaction, the Company will continue to operate under the OLAPLEX name and brand. OLAPLEX will no longer be listed on Nasdaq, and Advent International (“Advent”) will fully exit its investment in the Company at close.
The transaction is expected to:
Combine highly complementary strengths in the professional channel, where both companies have meaningful relationships with the stylist and salon community;Unlock new avenues for innovation through advanced technology, expanded capabilities and accelerated product development;Bring together OLAPLEX’s broad North American direct-to-consumer and specialty retail presence with Henkel’s international footprint, leading to expanded international reach; andCreate opportunities for innovation and growth, supported by OLAPLEX’s science-led approach and established position with consumers and Pro partners across demographics and hair needs. Amanda Baldwin, Chief Executive Officer of OLAPLEX, said, “Today marks an exciting next chapter for OLAPLEX. From our roots in the professional community to becoming one of the most trusted science-led brands in hair treatment, our journey has always been fueled by innovation and a deep commitment to stylists and consumers. This step is a testament to the momentum we’ve achieved in our transformation and the significant opportunities ahead for OLAPLEX to continue shaping the future of hair health and pursue long-term growth. I’m incredibly proud of what our team has accomplished and look forward to accelerating our product innovation, expanding our reach and continuing to deliver results for our Pro partners and customers around the world as part of the Henkel platform.”
John P. “JP” Bilbrey, Executive Chair of the OLAPLEX Board of Directors, added, “OLAPLEX’s growth reflects the strength of its science-led approach, its brand and the dedication of its team. We are proud to have supported Amanda and the entire OLAPLEX team as they drove brand momentum, scaled innovation and advanced significant operational transformation. We look forward to the opportunities ahead under Henkel’s stewardship.”
Since 2019, OLAPLEX has been backed by Advent, which helped scale the Company from a first-of-its-kind product to a science-led brand focused on hair health, supported by meaningful investments across product innovation, brand strength and operational excellence. The Company recently undertook a multi-year transformation program, which enhanced its innovation potential, marketing capabilities and go-to-market model and renewed engagement across stylist and consumer communities. As part of this, OLAPLEX also built out the people, processes and tools needed to drive executional excellence and efficiency on a global scale. These efforts, together with the Company’s science-led heritage and strong brand recognition, have positioned OLAPLEX well as it enters its next chapter under Henkel’s ownership.
Transaction Details
The transaction, which was approved by the OLAPLEX Board of Directors, is expected to close as soon as the second half of 2026, subject to regulatory approvals and other customary closing conditions. Advent, as holder of more than a majority of the voting power of the outstanding shares of OLAPLEX common stock, has approved the transaction by written consent. As a result, no further action by other OLAPLEX stockholders will be required to approve the transaction.
Advisors
J.P. Morgan Securities LLC is acting as financial advisor and Ropes & Gray LLP is serving as legal counsel to OLAPLEX.
About OLAPLEX
OLAPLEX is a foundational health and beauty company powered by breakthrough innovation and the professional hairstylist. Born in the lab and brought to the chair, our products are designed to enable Pros and their clients to achieve their best results and to provide consumers with a holistic healthy hair regimen. Founded in 2014, OLAPLEX revolutionized prestige hair care with its first-of-its-kind Complete Bond Technology™, which works by protecting, strengthening and relinking all three bonds during and after hair services. Since then, OLAPLEX has expanded into a full suite of hair health formulas. OLAPLEX’s award-winning products are sold globally through an omnichannel model serving the professional, specialty retail and direct-to-consumer channels.
About Advent International
Advent is a leading global private equity investor committed to working in partnership with management teams, entrepreneurs, and founders to help transform businesses. With 16 offices across five continents, we oversee more than USD $100 billion in assets under management* and have made 448 investments across 44 countries.
Since our founding in 1984, we have developed specialist market expertise across our five core sectors: business & financial services, consumer, healthcare, industrial, and technology. This approach is bolstered by our deep sub-sector knowledge, which informs every aspect of our investment strategy, from sourcing opportunities to working in partnership with management to execute value creation plans. We bring hands-on operational expertise to enhance and accelerate businesses.
As one of the largest privately-owned partnerships, our 655 colleagues leverage the full ecosystem of Advent’s global resources, including our Portfolio Support Group, insights provided by industry expert Operating Partners and Operations Advisors, as well as bespoke tools to support and guide our portfolio companies as they seek to achieve their strategic goals.
To learn more, visit our website or connect with us on LinkedIn.
*Assets under management (AUM) as of September 30, 2025. AUM includes assets attributable to Advent advisory clients as well as employee and third-party co-investment vehicles.
Forward-Looking Statements
This press release includes forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, these forward-looking statements relate to analyses and other information that are based on beliefs, expectations, assumptions, and forecasts of future results. These forward-looking statements are identified by their use of terms and phrases, such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will,” and other similar terms and phrases, including references to assumptions. Forward-looking statements include, without limitation, statements regarding the proposed transaction; the timing of and receipt of required regulatory filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; the potential benefits of the transaction, including the complementary strengths in the professional channel, ability to maximize scaled innovation, OLAPLEX’s direct-to-consumer and specialty retail presence, and opportunities for product development, geographic expansion; and the accuracy of any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the merger; the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, including circumstances requiring the Company to pay Parent a termination fee pursuant to the Merger Agreement; the ability of the parties to consummate the proposed transaction on a timely basis or at all; the satisfaction of the conditions precedent to the consummation of the proposed transaction, including the ability to secure regulatory approvals on the terms expected, at all or in a timely manner; the effects of the transaction (or the announcement or pendency thereof) on relationships with associates, customers, manufacturers, suppliers, employees (including the risks relating to the ability to retain or hire key personnel), other business partners or governmental entities; transaction costs; the risk that the merger will divert management’s attention from the Company’s ongoing business operations or otherwise disrupt the Company’s ongoing business operations; changes in the Company’s business during the period between now and the closing; certain restrictions during the pendency of the proposed transaction that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; risks associated with litigation relating to the proposed transaction; the timing and outcome of anticipated interactions with regulatory authorities; risks related to the Company’s business, including the Company’s dependence on the success of its business transformation plan, competition in the beauty industry, the Company’s ability to effectively maintain and promote a positive brand image, expand its brand awareness and maintain consumer confidence in the quality, safety and efficacy of its products, and the Company’s ability to anticipate and respond to market trends and changes in consumer preferences and execute on its growth strategies and expansion opportunities, including with respect to new product introductions; and the other factors identified under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC on March 5, 2026 and in the other documents that the Company files with the SEC from time to time. The forward-looking statements in this communication speak only as of the date of this communication. Olaplex undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by applicable law. The information set forth herein speaks only as of the date hereof.
No Offer or Solicitation
This press release is neither an offer to sell, nor a solicitation of an offer to buy any securities, the solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act and otherwise in accordance with applicable law.
Additional Information and Where to Find It
The Company will prepare and file an information statement on Schedule 14C for its stockholders with respect to the approval of the transaction described herein. When completed, the information statement will be mailed to the Company’s stockholders. You may obtain copies of all documents filed by the Company with the SEC regarding this transaction, free of charge, at the SEC’s website, www.sec.gov or from the Company website at https://ir.olaplex.com/sec-filings.
Company stockholders are urged to read all relevant documents filed with the SEC, including the Schedule 14C, as well as any amendments or supplements to these documents, carefully when they become available because they will contain important information about the transaction.
(Editor’s note: The future prices of benchmark tracking ETFs, the lede, the economic data and the headline were updated in the story.)
U.S. stock futures fell on Thursday following Wednesday’s advances. Futures of the major benchmark indices were lower.
U.S. initial jobless claims rose to 210,000 for the week ending March 21, a modest increase of 5,000 from the previous week's unrevised level. Despite this slight uptick, the labor market showed signs of underlying resilience as the four-week moving average edged down to 210,500.
Highlighting this strength, insured unemployment fell by 32,000 to 1.819 million for the week ending March 14, marking its lowest level since May 2024.
In a post on Truth Social early Thursday, President Donald Trump described Iranian negotiators as "very different" and "strange," claiming they are "begging" for a deal despite publicly saying they are only "looking at our proposal." He warned that Iran “better get serious soon,” or there may be "no turning back,” cautioning that the outcome "won't be pretty."
This came after Trump said Wednesday that Iran was eager to reach a deal to end nearly four weeks of fighting, contradicting Iran’s foreign minister, who said Tehran was reviewing a U.S. proposal but had no plans to negotiate an end to the conflict.
Meanwhile, the 10-year Treasury bond yielded 4.37%, and the two-year bond was at 3.94%. The CME Group's FedWatch tool‘s projections show markets pricing a 93.8% likelihood of the Federal Reserve leaving the current interest rates unchanged in its April meeting.
IndexPerformance (+/-)Dow Jones-0.47%S&P 500-0.55%Nasdaq 100-0.65%Russell 2000-0.92%Stocks In FocusOlaplex Holdings Benzinga’s Edge Stock Rankings indicate that OLPX maintains a weak price trend over the long, short, and medium terms. FiscalNote Holdings Benzinga’s Edge Stock Rankings indicate that NOTE maintains a weak trend in the long, short, and medium terms. Worthington Steel Worthington Steel Inc. (NYSE:WS) plunged 14.04% after reporting weaker-than-expected third-quarter financial results. Benzinga’s Edge Stock Rankings indicate that WS maintains a weak price trend over the short, medium, and long terms, with a solid value score. MillerKnoll MillerKnoll Inc. (NASDAQ:MLKN) slumped 19.16% after reporting worse-than-expected third-quarter financial results and issuing weak fourth-quarter earnings guidance. Benzinga’s Edge Stock Rankings indicate that MLKN maintains a weak trend in the short, long, and medium terms, with a poor growth score. Benzinga’s Edge Stock Rankings indicate that PONY maintains a weak price trend in the short, medium, and long terms. Cues From Last SessionConsumer discretionary, materials, and health care stocks led the S&P 500 higher on Wednesday, while energy and real estate shares finished in the red.
Insights From AnalystsAccording to BlackRock's March 2026 commentary, the firm has downgraded U.S. stocks to neutral as escalating Middle East conflict creates a significant “macro shock.”
This geopolitical instability has triggered a “sharp repricing in energy markets,” leading to expectations of a prolonged supply disruption that could drag on global growth by approximately 0.75%.
BlackRock highlights a growing “market disconnect,” noting that current equity prices do not yet reflect the “macro damage that energy pricing implies.” While the S&P 500 remains near record highs, the firm warns that higher energy costs and uncertainty will soon weigh on demand.
Economically, the “energy shock has further weakened the case for the Fed’s easing rates this year.” Market expectations have shifted dramatically from anticipating three rate cuts to “veering toward a hike.”
BlackRock suggests that the window for Fed intervention is “closing fast” as persistent inflation and high debt burdens keep bond yields elevated. Consequently, they are “dialing down tactical risk,” remaining cautious until tangible evidence of de-escalation appears.
Upcoming Economic DataHere's what investors will be keeping an eye on Thursday.
Commodities, Crypto, And Global Equity MarketsCrude oil futures were trading lower in the early New York session by 3.55% to hover around $93.53 per barrel.
Gold Spot US Dollar fell 1.72% to hover around $4,428.84 per ounce. Its last record high stood at $5,595.46 per ounce. The U.S. Dollar Index spot was 0.08% higher at the 99.6820 level.
Meanwhile, Bitcoin (CRYPTO: BTC) was trading 0.50% higher at $71,238.02 per coin, as per the last 24 hours.
Asian markets closed lower on Thursday, except India’s Nifty 50 index. South Korea's Kospi, Japan's Nikkei 225, China’s CSI 300, Australia's ASX 200, and Hong Kong's Hang Seng indices fell. European markets were also lower in early trade.
Photo courtesy: Shutterstock
Market News and Data brought to you by Benzinga APIs
Olaplex (OLPX) surges 49% premarket after agreeing to a $1.4B all-cash acquisition by Henkel (HENKY), at a 55% premium to prior close. JetBlue (JBLU) gains 13% on reports of exploring a potential sale to major U.S. airlines, though discussions are preliminary.
German consumer brand Henkel announced Thursday that it has agreed to acquire all of prestige haircare brand Olaplex for $1.4 billion.
The company said the deal, at an offer price of $2.06 per share, was unanimously approved by Olaplex's board of directors and marks an "important milestone" in Henkel's business strategy.
"The planned acquisition of OLAPLEX is fully in line with Henkel's strategy to expand its portfolio through compelling, value-adding M&A activities," Henkel CEO Carsten Knobel said in a statement. "This transaction allows us to expand our presence in premium hair care. The brand creates compelling opportunities for future growth and innovation."
Henkel owns brands like Got2b and Purex.
Olaplex said the deal represented a premium of more than 50% over its closing stock price on Wednesday and would allow the company to explore new opportunities for innovation and growth, as well as expand its international reach.
"This step is a testament to the momentum we've achieved in our transformation and the significant opportunities ahead for OLAPLEX to continue shaping the future of hair health and pursue long-term growth," Olaplex CEO Amanda Baldwin said in a statement.
Shares of the company, which closed on Wednesday around $1.30 per share, shot up 50% following the announcement.
Olaplex had been struggling as a public company over the past few years, dealing with the fallout of a lawsuit alleging hair loss and increased competition in the prestige hair care space.
Prior to the deal, Olaplex's stock had lost nearly 95% of its value since its initial public offering in 2021, when it opened at $25 per share during a boom for IPOs. It had been trying to turn around its business, including by launching a new product last month and working to rewrite its reputation among consumers.
Analysts had previously told CNBC that they were excited at the prospect that the company may go private.
Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Ademi LLP is investigating Olaplex (NASDAQ: OLPX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Henkel.
Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.
In the transaction, Olaplex stockholders will receive $2.06 per share in a cash transaction valued at approximately $1.4 billion. Olaplex insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Olaplex by imposing a significant penalty if Olaplex accepts a competing bid. We are investigating the conduct of the Olaplex board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Shares of Olaplex Holdings (OLPX) surged 50% on Thursday morning after the company agreed to be acquired by German consumer goods firm Henkel AG and Co. KGaA (HEN
Olaplex (OLPX 0.49%), a hair care treatment and protection specialist, closed Thursday at $2.01, up 51.13% for the session. The stock surged after news that German consumer goods behemoth Henkel agreed to acquire Olaplex for $2.06 per share in cash. Trading volume reached 104.6 million shares, about 2,904% above its three-month average of 3.5 million shares. Olaplex IPO'd in 2021 and has fallen 92% since going public.
How the markets moved todayS&P 500 fell 1.76% to finish Thursday at 6,476, while the Nasdaq Composite declined 2.38% to close at 21,408. Within personal care products, industry peers Estée Lauder Companies closed at $69.72, down 4.64%, and Procter & Gamble finished at $142.33, slipping 1.10% as investors reassessed sector growth prospects.
What this means for investorsOlaplex’s disappointing run as a publicly-traded company is coming to an end after the company agreed to be acquired for $2.06 per share in an all-cash deal with German consumer goods giant Henkel. The deal is worth $1.4 billion, far from Olaplex’s $15 billion market cap at its initial public offering in 2021.
When Olaplex first debuted on the market with its premium hair care products, it was growing sales by triple digits and boasted a 30% net profit margin. Since then, sales growth and profitability have turned negative, likely making the buyout a welcome relief. A relatively niche offering, Olaplex may be better suited in a broader portfolio of brands within Henkel rather than as a standalone company, so the deal makes sense to me.
Josh Kohn-Lindquist has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Olaplex Holdings, Inc. (NASDAQ: OLPX) related to its sale to Henkel US Operations Corporation. Under the terms of the proposed transaction, Olaplex shareholders are expected to receive $2.06 per share in cash. Is it a fair deal?
Click here for more info https://monteverdelaw.com/case/olaplex-holdings-inc/. It is free and there is no cost or obligation to you.
NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:
Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC
Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.
Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341
Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
Olaplex Holdings, Inc. (NASDAQ: OLPX - Get Free Report)'s share price hit a new 52-week high during trading on Thursday. The stock traded as high as $2.01 and last traded at $2.0050, with a volume of 71218940 shares changing hands. The stock had previously closed at $1.33. Key Headlines Impacting Olaplex Here are the key
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Olaplex Holdings, Inc. (NASDAQ: OLPX) to Henkel AG & Co. KGaA for $2.06 per share.Halper Sadeh encourages Olaplex shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected] investigation concerns whether Olaplex and its board of directors violated t.
Foxx Development (NASDAQ:FOXX – Get Free Report) and Olaplex (NASDAQ:OLPX – Get Free Report) are both small-cap consumer discretionary companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, earnings, profitability, risk and dividends.
Insider & Institutional Ownership 60.4% of Foxx Development shares are held by institutional investors. Comparatively, 87.4% of Olaplex shares are held by institutional investors. 31.6% of Foxx Development shares are held by company insiders. Comparatively, 4.3% of Olaplex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability This table compares Foxx Development and Olaplex’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Foxx Development -24.62% N/A -40.69% Olaplex -2.19% 1.07% 0.60% Earnings & Valuation This table compares Foxx Development and Olaplex”s gross revenue, earnings per share and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Foxx Development $65.92 million 0.59 -$9.02 million ($2.26) -2.46 Olaplex $422.96 million 3.21 -$9.25 million ($0.01) -203.00 Foxx Development has higher earnings, but lower revenue than Olaplex. Olaplex is trading at a lower price-to-earnings ratio than Foxx Development, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk Foxx Development has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500. Comparatively, Olaplex has a beta of 2, meaning that its stock price is 100% more volatile than the S&P 500.
Analyst Recommendations This is a summary of recent ratings and target prices for Foxx Development and Olaplex, as reported by MarketBeat.com.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foxx Development 1 0 0 0 1.00 Olaplex 1 5 1 0 2.00 Olaplex has a consensus price target of $1.89, indicating a potential downside of 7.04%. Given Olaplex’s stronger consensus rating and higher possible upside, analysts plainly believe Olaplex is more favorable than Foxx Development.
Summary Olaplex beats Foxx Development on 11 of the 14 factors compared between the two stocks.
About Foxx Development (Get Free Report)
Foxx Development Holdings Inc. is a consumer electronics and integrated Internet-of-Things solution company catering to both retail and institutional clients. The company currently sells a diverse range of products including mobile phones, tablets and other consumer electronics devices principally in United State and is in the process of developing and distributing end-to-end communication terminals and IoT solutions. Foxx Development Holdings Inc., formerly known as Acri Capital Acquisition Corporation, is based in Austin, TX.
About Olaplex (Get Free Report)
Olaplex Holdings, Inc. develops, manufactures, and sells hair care products in the United States and internationally. The company offers hair care shampoos and conditioners for use in treatment, maintenance, and protection of hair, as well as oil, moisture mask, and nourishing hair serum. It provides hair care products to professional hair salons, retailers, and everyday consumers. The company distributes its products through professional distributors in salons, directly to retailers for sale in their physical stores, e-commerce sites, and its website, Olaplex.com, as well as third party e-commerce platforms. The company was founded in 2014 and is based in Santa Barbara, California.
Receive News & Ratings for Foxx Development Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foxx Development and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEReviewing Alarm.com (NASDAQ:ALRM) and Brady (NYSE:BRC)
NEXT HEADLINE »Comparing Indaptus Therapeutics (NASDAQ:INDP) & Aldeyra Therapeutics (NASDAQ:ALDX)
BALA CYNWYD, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Olaplex Holdings, Inc. (“Olaplex” or the “Company”) (Nasdaq - OLPX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Henkel AG & Co. KGaA (“Henkel”) for $2.06 per share in a cash transaction, representing an equity value of approximately $1.4 billion.
The investigation concerns whether the Olaplex Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Gilead Sciences is paying fair value to shareholders of the Company.
If you own shares of Olaplex stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at [email protected], visit https://www.brodskysmith.com/cases/olaplex-holdings-inc-nasdaq-olpx/, or call toll free 855-576-4847.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Olaplex Holdings, Inc. (NasdaqGS: OLPX) to Henkel AG & Co. KGaA. Under the terms of the proposed transaction, shareholders of Olaplex will receive $2.06 in cash for each share of Olaplex that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequ.
Alto Ingredients (NASDAQ:ALTO – Get Free Report) and Olaplex (NASDAQ:OLPX – Get Free Report) are both small-cap consumer discretionary companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.
Analyst Ratings This is a breakdown of recent ratings and recommmendations for Alto Ingredients and Olaplex, as provided by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alto Ingredients 0 1 0 1 3.00 Olaplex 1 5 1 0 2.00 Olaplex has a consensus price target of $1.89, indicating a potential downside of 7.04%. Given Olaplex’s higher probable upside, analysts clearly believe Olaplex is more favorable than Alto Ingredients.
Valuation and Earnings This table compares Alto Ingredients and Olaplex”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alto Ingredients $917.93 million 0.39 $13.34 million $0.16 29.19 Olaplex $422.96 million 3.21 -$9.25 million ($0.01) -203.00 Alto Ingredients has higher revenue and earnings than Olaplex. Olaplex is trading at a lower price-to-earnings ratio than Alto Ingredients, indicating that it is currently the more affordable of the two stocks.
Profitability This table compares Alto Ingredients and Olaplex’s net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Alto Ingredients 1.45% 2.99% 1.69% Olaplex -2.19% 1.07% 0.60% Risk & Volatility Alto Ingredients has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Comparatively, Olaplex has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500.
Insider & Institutional Ownership 42.4% of Alto Ingredients shares are held by institutional investors. Comparatively, 87.4% of Olaplex shares are held by institutional investors. 5.3% of Alto Ingredients shares are held by insiders. Comparatively, 4.3% of Olaplex shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary Alto Ingredients beats Olaplex on 10 of the 15 factors compared between the two stocks.
About Alto Ingredients (Get Free Report)
Alto Ingredients, Inc. produces, distributes, and markets specialty alcohols, renewable fuel, and essential ingredients in the United States. The company operates in three segments: Marketing and Distribution, Pekin Campus Production, and Western Production. It offers specialty alcohols used in mouthwash, cosmetics, pharmaceuticals, hand sanitizers, disinfectants, and cleaners for health, home, and beauty markets; grain neutral spirits used in alcoholic beverages and vinegar, as well as corn germ used in corn oils in the food and beverage markets; alcohols and other products for paint applications and fertilizers in the industrial and agriculture markets; and essential ingredients include dried yeast, corn protein meal, corn protein feed, distiller's grains, and liquid feed for commercial animal feed and pet food applications, as well as yeast for human consumption. The company also provides fuel-grade ethanol used as transportation fuel and distillers corn oil used as a biodiesel feedstock, as well as fuel-grade ethanol produced by third parties. In addition, it offers transportation, storage, and delivery services through third-party service providers. The company sells ethanol to integrated oil companies and gasoline marketers; essential ingredient feed products to dairies and feedlots; and corn oil to poultry, renewable diesel, and biodiesel customers. It operates alcohol production facilities. The company was formerly known as Pacific Ethanol, Inc. and changed its name to Alto Ingredients, Inc. in January 2021. Alto Ingredients, Inc. was founded in 2003 and is headquartered in Pekin, Illinois.
About Olaplex (Get Free Report)
Olaplex Holdings, Inc. develops, manufactures, and sells hair care products in the United States and internationally. The company offers hair care shampoos and conditioners for use in treatment, maintenance, and protection of hair, as well as oil, moisture mask, and nourishing hair serum. It provides hair care products to professional hair salons, retailers, and everyday consumers. The company distributes its products through professional distributors in salons, directly to retailers for sale in their physical stores, e-commerce sites, and its website, Olaplex.com, as well as third party e-commerce platforms. The company was founded in 2014 and is based in Santa Barbara, California.
Receive News & Ratings for Alto Ingredients Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Ingredients and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEComparing United Internet (OTCMKTS:UDIRF) and LivePerson (NASDAQ:LPSN)
NEXT HEADLINE »Reviewing Primoris Services (NYSE:PRIM) and SOLV Energy (NASDAQ:MWH)
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Olaplex (NASDAQ: OLPX) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Henkel.
Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.
In the transaction, Olaplex stockholders will receive $2.06 per share in a cash transaction valued at approximately $1.4 billion. Olaplex insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Olaplex by imposing a significant penalty if Olaplex accepts a competing bid. We are investigating the conduct of the Olaplex board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
State of Alaska Department of Revenue cut its stake in Olaplex Holdings, Inc. (NASDAQ:OLPX – Free Report) by 47.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 606,213 shares of the company’s stock after selling 549,497 shares during the quarter. State of Alaska Department of Revenue owned about 0.09% of Olaplex worth $810,000 at the end of the most recent quarter.
Several other hedge funds also recently added to or reduced their stakes in OLPX. Chilton Capital Management LLC acquired a new position in shares of Olaplex during the third quarter worth about $26,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Olaplex during the third quarter worth about $30,000. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Olaplex during the third quarter worth about $32,000. BNP Paribas Financial Markets lifted its stake in shares of Olaplex by 95.4% during the third quarter. BNP Paribas Financial Markets now owns 29,707 shares of the company’s stock worth $39,000 after purchasing an additional 14,507 shares in the last quarter. Finally, Savant Capital LLC acquired a new stake in Olaplex in the third quarter valued at approximately $43,000. 87.37% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth OLPX has been the subject of several recent research reports. Jefferies Financial Group reaffirmed a “buy” rating on shares of Olaplex in a research report on Wednesday, March 4th. Northland Securities downgraded shares of Olaplex from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Olaplex in a research report on Thursday, January 22nd. Zacks Research upgraded shares of Olaplex from a “strong sell” rating to a “hold” rating in a report on Thursday, February 19th. Finally, Telsey Advisory Group boosted their price objective on shares of Olaplex from $2.00 to $2.06 and gave the stock a “market perform” rating in a report on Friday, March 27th. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Olaplex currently has an average rating of “Hold” and a consensus target price of $1.92.
View Our Latest Stock Analysis on Olaplex
Insider Activity at Olaplex In related news, insider Trisha L. Fox sold 25,421 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $1.26, for a total value of $32,030.46. Following the sale, the insider directly owned 1,080,363 shares of the company’s stock, valued at $1,361,257.38. This represents a 2.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel John C. Duffy sold 34,962 shares of the company’s stock in a transaction on Thursday, March 12th. The shares were sold at an average price of $1.26, for a total transaction of $44,052.12. Following the completion of the sale, the general counsel directly owned 982,855 shares in the company, valued at $1,238,397.30. This represents a 3.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 215,442 shares of company stock valued at $271,457 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.
Olaplex Price Performance Shares of NASDAQ OLPX opened at $2.03 on Thursday. Olaplex Holdings, Inc. has a fifty-two week low of $0.99 and a fifty-two week high of $2.04. The business has a 50 day moving average price of $1.68 and a two-hundred day moving average price of $1.44. The company has a quick ratio of 4.00, a current ratio of 4.58 and a debt-to-equity ratio of 0.40. The firm has a market cap of $1.36 billion, a PE ratio of -203.00 and a beta of 2.01.
Olaplex (NASDAQ:OLPX – Get Free Report) last issued its quarterly earnings data on Thursday, March 5th. The company reported $0.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.01. The firm had revenue of $105.12 million during the quarter, compared to analyst estimates of $104.21 million. Olaplex had a positive return on equity of 1.07% and a negative net margin of 2.19%.Olaplex’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.01 EPS. Sell-side analysts expect that Olaplex Holdings, Inc. will post 0.09 earnings per share for the current fiscal year.
About Olaplex (Free Report)
Olaplex, Inc (NASDAQ: OLPX) is a specialty haircare company known for its patented bond-building technology designed to repair and strengthen hair from within. The company’s core offerings encompass a range of professional salon treatments and at-home maintenance products that target chemical damage, breakage and split ends. Olaplex formulations are built around a proprietary active ingredient that works at the molecular level to rebuild disulfide bonds broken during bleaching, coloring and heat styling processes.
Founded in 2014 and headquartered in Irvine, California, Olaplex initially gained traction among high-end salons before expanding into broader retail channels.
Recommended Stories Five stocks we like better than Olaplex
Receive News & Ratings for Olaplex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olaplex and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINESterling Infrastructure, Inc. $STRL Position Trimmed by State of Alaska Department of Revenue
NEXT HEADLINE »GB Group’s (GBG) “Buy” Rating Reaffirmed at Shore Capital Group
NEW YORK, NY, May 11, 2026 (GLOBE NEWSWIRE) -- Olaplex Holdings, Inc. (NASDAQ: OLPX) ("OLAPLEX" or the "Company") today announced financial results for the first quarter ended March 31, 2026.
Amanda Baldwin, OLAPLEX’s Chief Executive Officer, commented: "We delivered a solid start to the year with positive quarterly sell-through led by the successful launch of No. 3 PLUS. Through the disciplined operational execution of our transformation priorities, our higher sales translated to a strong quarter. I want to again thank the entire Olaplex team for their continued dedication and commitment to our transformation."
For the first quarter of 2026 compared to the first quarter of 2025:
Net sales increased 2.5% to $99.4 million; By channel: Specialty Retail decreased 13.3% to $33.4 million;Professional increased 12.3% to $38.8 million;Direct-To-Consumer increased 13.8% to $27.2 million; Net sales decreased 3.5% in the United States and increased 8.6% internationally; Net loss was $5.3 million, as compared to net income of $0.5 million for the first quarter of 2025;Diluted net loss per share was $(0.01), as compared to $0.00 for the first quarter of 2025. Three Months Ended March 31, 2026 Results
(Amounts in thousands, except per share and share data) Three Months Ended March 31, 2026 2025 % ChangeNet Sales $99,369 $96,978 2.5%Gross Profit $71,660 $67,356 6.4%Gross Profit Margin 72.1% 69.5% Adjusted Gross Profit $74,076 $69,748 6.2%Adjusted Gross Profit Margin 74.5% 71.9% SG&A $65,951 $47,987 37.4%Adjusted SG&A $55,038 $44,349 24.1%Net (Loss) Income $(5,287) $465 (1,237.0)%Adjusted Net Income $10,648 $13,161 (19.1)%Adjusted EBITDA $18,978 $25,664 (26.1)%Adjusted EBITDA Margin 19.1% 26.5% Diluted Net Loss Per Share $(0.01) $0.00 —%Adjusted Diluted Net Income Per Share $0.02 $0.02 —%
Adjusted gross profit, adjusted gross profit margin, adjusted SG&A, adjusted net income, adjusted EBITDA, adjusted EBITDA margin and adjusted diluted net income per share are measures that are not calculated or presented in accordance with generally accepted accounting principles in the United States of America ("GAAP"). For more information about how we use these non-GAAP financial measures in our business, the limitations of these measures, and a reconciliation of these measures to the most directly comparable GAAP measures, please see "Disclosure Regarding Non-GAAP Financial Measures" and the reconciliation tables that accompany this release.
Balance Sheet
As of March 31, 2026, the Company had $326.2 million of cash and cash equivalents, compared to $318.7 million as of December 31, 2025. Inventory at the end of the first quarter of 2026 was $66.4 million, compared to $60.2 million at December 31, 2025. Long-term debt, net of current portion and deferred debt issuance costs was $352.5 million as of March 31, 2026, compared to $352.3 million as of December 31, 2025.
Fiscal Year 2026 Guidance, Webcast and Conference Call Information
On March 26, 2026, OLAPLEX announced that it had entered into a definitive agreement to be acquired by Henkel AG & Co. KGaA (“Henkel”), a leading global manufacturer of well-known consumer and industrial brands, for $2.06 per share in a cash transaction, representing an equity value of approximately $1.4 billion. The transaction represents a premium of approximately 55% over OLAPLEX’s closing stock price on March 25, 2026 and a premium of approximately 45% over the volume weighted average price of OLAPLEX’s shares for the 30 trading days ended March 25, 2026.
In light of the transaction, OLAPLEX will not host a conference call to discuss its first quarter 2026 results and will not be providing or updating previously issued financial guidance.
About OLAPLEX
OLAPLEX is a foundational health and beauty company powered by breakthrough innovation and the professional hairstylist. Born in the lab and brought to the chair, our products are designed to enable Pros and their clients to achieve their best results and to provide consumers with a holistic healthy hair regimen. Founded in 2014, OLAPLEX revolutionized prestige hair care with its category creating Complete Bond Technology™, which works by protecting, strengthening and relinking all three bonds during and after hair services. Since then, OLAPLEX has expanded into a full suite of hair health formulas. OLAPLEX’s award-winning products are sold globally through an omnichannel model serving the professional, specialty retail, and direct-to-consumer channels.
This press release includes certain forward-looking statements and information relating to the Company that are based on the beliefs of management as well as assumptions made by, and information currently available to, the Company. These forward-looking statements include, but are not limited to, statements about: the proposed transaction (the “Merger”) with Henkel; the Company’s business transformation plans; and other statements contained in this press release that are not historical or current facts. When used in this press release, words such as "may," "will," “could," "should," "intend," "potential," "continue," "anticipate," "believe," "estimate," "expect," "plan," "target," "predict," "project," "forecast," "seek" and similar expressions as they relate to the Company are intended to identify forward-looking statements.
The forward-looking statements in this press release reflect the Company’s current expectations and projections about future events and financial trends that management believes may affect the Company’s business, financial condition and results of operations. These statements are predictions based upon assumptions that may not prove to be accurate, and they are not guarantees of future performance. As such, you should not place significant reliance on the Company’s forward-looking statements. Neither the Company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements, including any such statements taken from third party industry and market reports.
Forward-looking statements involve known and unknown risks, inherent uncertainties and other factors that are difficult to predict which may cause the Company’s actual results, performance, time frames or achievements to be materially different from any future results, performance, time frames or achievements expressed or implied by the forward-looking statements, including, without limitation: uncertainties as to the timing or completion of the Merger, including the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement with Henkel (the “Merger Agreement”) and circumstances requiring the Company to pay a termination fee or damages under the Merger Agreement; the effects of the proposed Merger (or the announcement or pendency thereof) on relationships with associates, customers, manufacturers, suppliers, employees (including the risks relating to the ability to retain or hire key personnel), other business partners or governmental entities; the risk that the proposed Merger will divert management's attention from the Company's ongoing business operations or otherwise disrupt the Company's ongoing business operations; risks associated with litigation relating to the proposed Merger; the Company’s dependence on the success of its business transformation plan; competition in the beauty industry; the Company’s ability to effectively maintain and promote a positive brand image, expand its brand awareness and maintain consumer confidence in the quality, safety and efficacy of its products; the Company’s ability to anticipate and respond to market trends and changes in consumer preferences and execute on its growth strategies and expansion opportunities, including with respect to new product introductions; the Company’s ability to develop, manufacture and effectively and profitably market and sell future products; the Company’s ability to attract new customers and consumers and encourage consumer spending across its product portfolio; the Company’s ability to successfully implement new or additional marketing efforts; the Company’s relationships with and the capabilities and performance of its suppliers, manufacturers, distributors and retailers and the Company’s ability to manage its supply chain, including sourcing, manufacturing and quality control; the Company's dependence on a limited number of customers for a large portion of its net sales; the Company’s ability to limit the illegal distribution and sale by third parties of counterfeit versions of its products or the unauthorized diversion by third parties of its products; the Company’s ability to accurately forecast customer and consumer demand for its products; impacts on the Company’s business from political, regulatory, economic, trade and other risks associated with operating internationally; the Company’s ability to attract and retain senior management and other qualified personnel; the Company’s reliance on its and its third-party service providers’ information technology; the Company’s ability to maintain the security of confidential information; the Company’s ability to establish and maintain intellectual property protection for its products, as well as the Company’s ability to operate its business without infringing, misappropriating or otherwise violating the intellectual property rights of others; the outcome of litigation and regulatory proceedings; the impact of changes in federal, state and international laws, regulations and administrative policy, tariffs and other trade policies; the Company’s existing and any future indebtedness, including the Company’s ability to comply with affirmative and negative covenants under its credit agreement; the Company’s ability to service its existing indebtedness and obtain additional capital to finance operations and its growth opportunities; volatility of the Company’s stock price; the Company’s “controlled company” status and the influence of investment funds affiliated with Advent International, L.P. over the Company; the impact of general economic conditions, disruptions in business conditions, and the financial strength of the Company’s consumers and customers on the Company’s business; fluctuations in the Company’s quarterly results of operations; changes in the Company’s tax rates and the Company’s exposure to tax liability; the Company's ability to integrate or realize the intended benefits of its acquisitions or strategic investments; and the other factors identified under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") and in the other documents that the Company files with the SEC from time to time.
Many of these factors are macroeconomic in nature and are, therefore, beyond the Company’s control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company’s actual results, performance or achievements may vary materially from those described in this press release as anticipated, believed, estimated, expected, intended, planned or projected. The forward-looking statements in this press release represent management’s views as of the date hereof. Unless required by law, the Company neither intends nor assumes any obligation to update these forward-looking statements for any reason after the date hereof to conform these statements to actual results or to changes in the Company’s expectations or otherwise.
Disclosure Regarding Non-GAAP Financial Measures
In addition to the financial measures presented in this release in accordance with GAAP, the Company has included certain non-GAAP financial measures, including adjusted EBITDA, adjusted EBITDA margin, adjusted gross profit, adjusted gross profit margin, adjusted SG&A, adjusted net income and adjusted basic and diluted net income per share. Management believes these non-GAAP financial measures, when taken together with the Company’s financial results presented in accordance with GAAP, provide meaningful supplemental information regarding the Company’s operating performance and facilitate internal comparisons of its historical operating performance on a more consistent basis by excluding certain items that may not be indicative of its business, results of operations or outlook. In particular, management believes that the use of these non-GAAP measures may be helpful to investors as they are measures used by management in assessing the health of the Company’s business, determining incentive compensation and evaluating its operating performance, as well as for internal planning and forecasting purposes.
The Company calculates adjusted EBITDA as net income (loss), adjusted to exclude: (1) interest expense, net; (2) income tax (benefit) provision; (3) depreciation and amortization; (4) share-based compensation expense; (5) certain litigation-related expenses and (6) Merger transaction-related costs. The Company calculates adjusted EBITDA margin by dividing adjusted EBITDA by net sales. The Company calculates adjusted gross profit as gross profit, adjusted to exclude amortization of patented formulations. The Company calculates adjusted gross profit margin by dividing adjusted gross profit by net sales. The Company calculates adjusted SG&A as SG&A, adjusted to exclude: (1) share-based compensation expense, (2) certain litigation-related expenses and (3) Merger transaction-related costs. The Company calculates adjusted net income as net income (loss), adjusted to exclude: (1) amortization of intangible assets (excluding software); (2) share-based compensation expense; (3) certain litigation-related expenses; (4) Merger transaction-related costs; and (5) tax effect of non-GAAP adjustments. The Company calculates adjusted basic and diluted net income per share as adjusted net income divided by weighted average basic and diluted shares outstanding, respectively. Please refer to "Reconciliation of Non-GAAP Financial Measures to GAAP Equivalents" located in the financial supplement in this release for further information regarding these adjustments for the periods presented.
Please refer to "Reconciliation of Non-GAAP Financial Measures to GAAP Equivalents" located in the financial supplement in this release for a reconciliation of these non-GAAP metrics to their most directly comparable financial measure stated in accordance with GAAP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except per share and share data)
(Unaudited)
March 31,
2026 December 31,
2025Assets Current Assets: Cash and cash equivalents$326,169 $318,731 Accounts receivable, net of allowances of $14,503 and $18,123 37,501 29,013 Inventory 66,364 60,215 Prepaid expenses and other current assets 16,227 62,387 Total current assets 446,261 470,346 Property and equipment, net 1,516 1,422 Intangible assets, net 834,864 847,821 Goodwill 168,300 168,300 Deferred tax assets — 46 Other assets 9,253 9,552 Total assets$1,460,194 $1,497,487 Liabilities and stockholders’ equity Current Liabilities: Accounts payable$29,184 $8,117 Accrued expenses and other current liabilities 32,758 85,304 Current portion of Related Party payable pursuant to Tax Receivable Agreement 9,206 9,206 Total current liabilities 71,148 102,627 Long-term debt 352,484 352,290 Deferred tax liabilities 929 5,283 Related Party payable pursuant to Tax Receivable Agreement 155,858 155,858 Other liabilities 1,789 2,039 Total liabilities 582,208 618,097 Commitments and Contingencies Stockholders’ equity: Common stock, $0.001 par value per share; 2,000,000,000 shares authorized, 671,711,593 and 669,076,651 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively 672 669 Preferred stock, $0.001 par value per share; 25,000,000 shares authorized and no shares issued and outstanding — — Additional paid-in capital 346,086 342,345 Accumulated other comprehensive loss (198) (337)Retained earnings 531,426 536,713 Total stockholders’ equity 877,986 879,390 Total liabilities and stockholders’ equity$1,460,194 $1,497,487 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME
(amounts in thousands, except per share and share data)
(Unaudited)
Three Months Ended
March 31, 2026 2025 Net sales$99,369 $96,978 Cost of sales: Cost of product (excluding amortization) 25,293 27,230 Amortization of patented formulations 2,416 2,392 Total cost of sales 27,709 29,622 Gross profit 71,660 67,356 Operating expenses: Selling, general, and administrative 65,951 47,987 Amortization of other intangible assets 10,820 10,893 Total operating expenses 76,771 58,880 Operating (loss) income (5,111) 8,476 Interest expense 7,132 13,725 Interest income (2,702) (5,952)Other expense (income), net 142 (178)(Loss) Income before provision for income taxes (9,683) 881 Income tax (benefit) provision (4,396) 416 Net (loss) income$(5,287) $465 Net (loss) income per share: Basic$(0.01) $0.00 Diluted$(0.01) $0.00 Weighted average common shares outstanding: Basic 669,942,446 664,685,462 Diluted 669,942,446 666,460,714 Other comprehensive income: Unrealized gain on derivatives, net of income tax effect$139 $17 Total other comprehensive income 139 17 Comprehensive (loss) income$(5,148) $482 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts in thousands)
(Unaudited)
Three Months Ended
March 31, 2026 2025 Cash flows from operating activities Net (loss) income$(5,287) $465 Adjustments to reconcile net (loss) income to net cash provided by (used in) operating activities 12,786 (3,382)Net cash provided by (used in) operating activities 7,499 (2,917)Net cash used in investing activities (288) (996)Net cash provided by (used in) financing activities 227 (1,161)Net increase (decrease) in cash and cash equivalents 7,438 (5,074)Cash and cash equivalents - beginning of year 318,731 585,967 Cash and cash equivalents - end of period$326,169 $580,893 Reconciliation of Non-GAAP Financial Measures to GAAP Equivalents
(amounts in thousands, except per share and share data)
(Unaudited) The following tables present a reconciliation of net (loss) income, gross profit and SG&A, as the most directly comparable financial measure stated in accordance with U.S. GAAP, to adjusted EBITDA, adjusted EBITDA margin, adjusted gross profit, adjusted gross profit margin, adjusted SG&A, adjusted net income and adjusted net income per share for each of the periods presented.
Three Months Ended
March 31, 2026 2025 Reconciliation of Net (Loss) Income to Adjusted EBITDA Net (loss) income$(5,287) $465 Depreciation and amortization of intangible assets 13,318 13,372 Interest expense, net 4,430 7,773 Income tax (benefit) provision (4,396) 416 Share-based compensation expense 3,517 2,918 Certain litigation-related expenses(1) — 720 Merger transaction-related costs(2) 7,396 — Adjusted EBITDA$18,978 $25,664 Adjusted EBITDA margin 19.1% 26.5% Three Months Ended
March 31, 2026 2025 Reconciliation of Gross Profit to Adjusted Gross Profit Gross profit$71,660 $67,356 Amortization of patented formulations 2,416 2,392 Adjusted gross profit$74,076 $69,748 Adjusted gross profit margin 74.5% 71.9% Three Months Ended
March 31, 2026 2025 Reconciliation of SG&A to Adjusted SG&A SG&A$65,951 $47,987 Share-based compensation expense (3,517) (2,918)Certain litigation-related expenses(1) — (720)Merger transaction-related costs(2) (7,396) — Adjusted SG&A$55,038 $44,349 Three Months Ended
March 31, 2026 2025 Reconciliation of Net (Loss) Income to Adjusted Net Income Net (loss) income$(5,287) $465 Amortization of intangible assets (excluding software) 12,599 12,574 Share-based compensation expense 3,517 2,918 Certain litigation-related expenses(1) — 720 Merger transaction-related costs(2) 7,396 — Tax effect of adjustments (7,577) (3,516)Adjusted net income$10,648 $13,161 Adjusted net income per share: Basic$0.02 $0.02 Diluted$0.02 $0.02 Weighted average diluted shares outstanding(3) 674,802,028 666,460,714 (1)Represented litigation costs related to the Lilien securities class action. The Company considers litigation costs related to the Lilien securities class action, as described in Note 12 to the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2026, to be non-recurring and non-ordinary. The Company believes adjusting for such costs provides investors with meaningful information regarding the Company’s core operating performance.(2)Represents non-recurring and non-ordinary costs related to the definitive agreement to be acquired by Henkel. (3)Weighted average diluted shares outstanding for the three months ended March 31, 2026 differ from the GAAP presentation on the Company's Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income due to the Company being in a loss position on an unadjusted basis. Contacts:
For the quarter ended March 2026, Olaplex Holdings, Inc. (OLPX - Free Report) reported revenue of $99.37 million, up 2.5% over the same period last year. EPS came in at $0.02, compared to $0 in the year-ago quarter.
The reported revenue represents a surprise of +6.1% over the Zacks Consensus Estimate of $93.66 million. With the consensus EPS estimate being $0.01, the EPS surprise was +42.86%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Olaplex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue- Professional: $38.79 million versus $35.26 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +12.4% change.Revenue- DTC: $27.17 million versus the five-analyst average estimate of $23.97 million. The reported number represents a year-over-year change of +13.7%.Revenue- Specialty retail: $33.41 million versus $35.26 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -13.4% change.View all Key Company Metrics for Olaplex here>>>
Shares of Olaplex have returned +0.7% over the past month versus the Zacks S&P 500 composite's +9.1% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- Olaplex Holdings, Inc. (NASDAQ: OLPX) ("OLAPLEX" or the "Company") today released the following pursuant to an Order of the U.S. District Court for the Central District of California.
UNITED STATES DISTRICT COURT
CENTRAL DISTRICT OF CALIFORNIA
IN RE OLAPLEX HOLDINGS, INC. STOCKHOLDER DERIVATIVE LITIGATION Lead Case No.: 2:23-cv-09712-SVW-SKThis Document Relates To: ALL ACTIONS.
NOTICE OF PENDENCY AND PROPOSED SETTLEMENT
OF STOCKHOLDER DERIVATIVE MATTERS
AND SETTLEMENT HEARING
TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF OLAPLEX HOLDINGS INC. (“OLAPLEX” OR THE “COMPANY”) COMMON STOCK (TICKER SYMBOL: OLPX) AS OF APRIL 24, 2026, WHO CONTINUE TO OWN SUCH SHARES (“CURRENT OLAPLEX SHAREHOLDERS”).
PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. THIS NOTICE RELATES TO A PROPOSED SETTLEMENT AND DISMISSAL WITH PREJUDICE OF SHAREHOLDER DERIVATIVE LITIGATION AND CONTAINS IMPORTANT INFORMATION REGARDING YOUR RIGHTS.
YOUR RIGHTS MAY BE AFFECTED.
IF THE COURT APPROVES THE SETTLEMENT AND DISMISSAL OF THE DERIVATIVE MATTERS, OLAPLEX SHAREHOLDERS WILL BE FOREVER BARRED FROM CONTESTING THE APPROVAL OF THE PROPOSED SETTLEMENT AND DISMISSAL WITH PREJUDICE, AND FROM PURSUING PLAINTIFFS’ RELEASED CLAIMS.
THIS ACTION IS NOT A “CLASS ACTION.” THUS, THERE IS NO COMMON FUND UPON WHICH YOU CAN MAKE A CLAIM FOR A MONETARY PAYMENT.
On April 24, 2026, Plaintiffs, nominal defendant Olaplex, Advent International Corporation, and the Individual Defendants entered into a Stipulation and Agreement of Settlement (the “Stipulation”) to settle: the shareholder derivative actionsi styled Ciuffo v. Dagousset, et al., Case No. 2:23-cv-09712-SVW-SK and Hutchinson v. Advent International Corporation, et al., Case No. 2:24-cv-02364, consolidated as In re Olaplex Holdings, Inc. Stockholder Derivative Litigation, Lead Case No. 2:23-cv-09712-SVW-SK (the “Consolidated Derivative Action”), filed derivatively on behalf of Olaplex and pending in the United States District Court for the Central District of California (the “Court”); and the Section 220 demand for inspection of the Company’s books and records made by stockholder Kajeel Patel (the “Demand” and with the Consolidated Derivative Action, the “Derivative Matters”).ii The Settlement, which is subject to the approval of the Court, is intended by the Parties to fully, finally, and forever compromise, settle, release, resolve, and dismiss with prejudice the Released Claims upon and subject to the terms and conditions set forth in the Stipulation. The proposed Settlement requires the Company to adopt certain corporate governance reforms (“Reforms”), as outlined in Exhibit A to the Stipulation, and provides that Defendants shall cause their insurers to pay an agreed-to Fee and Expense Amount to Plaintiffs’ Counsel of $700,000, subject to Court approval, and that Plaintiffs’ Counsel may also move the Court to approve Service Awards to each of the three Plaintiffs, to be paid from the Fee and Expense Amount, in the amount of two thousand five hundred dollars ($2,500.00) each.
This Notice is a summary only and does not describe all of the details of the Stipulation. For full details of the matters discussed in this summary, please see the full Stipulation by visiting the SEC Filings portion of Olaplex’s website at https://ir.olaplex.com/sec-filings/all-sec-filings, reviewing Olaplex’s U.S. Securities and Exchange Commission (“SEC”) filings, contacting Plaintiffs’ Counsel at the addresses listed below, or inspecting the full Stipulation filed with the Clerk of the Court.
Summary
On May 7, 2026, the Court entered an order preliminarily approving the Stipulation and the Settlement contemplated therein (the “Preliminary Approval Order”) and providing for the notice of the Settlement to be disseminated to Current Olaplex Shareholders. The Preliminary Approval Order further provides that the Court will hold a hearing (the “Settlement Hearing”) on July 27, 2026 at 1:30 p.m. before the Honorable Stephen V. Wilson, in Courtroom 10A of the First Street United States Courthouse, 350 West 1st Street, Suite 4311 Los Angeles, CA 90012-4565, with the discretion to proceed telephonically or remotely, to, among other things: (i) determine whether the proposed Settlement is fair, reasonable, and adequate and in the best interests of the Company and its shareholders; (ii) consider any objections to the Settlement submitted in accordance with this Notice; (iii) determine whether a judgment should be entered dismissing all claims in the Consolidated Derivative Action with prejudice, and releasing Plaintiffs’ Released Claims against Defendants’ Released Persons (the “Judgment”); (iv) consider the payment to Plaintiffs’ Counsel of attorneys’ fees and expenses; (v) consider the payment of Service Awards to the three Plaintiffs, which shall be funded from the attorneys’ fees and expenses awarded by the Court; and (vi) consider any other matters that may properly be brought before the Court in connection with the Settlement. Upon final approval of the Settlement, the Demand will be withdrawn.
Upon the Effective Date, Olaplex, Plaintiffs, and each of the Current Olaplex Shareholders shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever released, relinquished, and discharged their right to assert derivatively on behalf of the Company any and all of Plaintiffs’ Released Claims (including Unknown Claims) against Defendants’ Released Persons, and shall be permanently barred and enjoined from instituting, commencing, or prosecuting derivatively on behalf of the Company any and all of Plaintiffs’ Released Claims against the Defendants’ Released Persons. In addition, upon that date, Olaplex shall be deemed to have, and by operation of the law and of the Judgment shall have, fully, finally, and forever released, relinquished and discharged its right to assert directly any and all of Plaintiffs’ Released Claims against Defendants’ Released Persons, and shall be permanently barred and enjoined from instituting, commencing, or prosecuting any of Plaintiffs’ Released Claims against Defendants’ Released Persons except to enforce the releases and other terms and conditions contained in this Stipulation and/or the Judgment entered pursuant thereto.
Upon the Effective Date, Defendants shall be deemed to have, and by operation of the Judgment shall have, fully, finally, and forever released, relinquished, and discharged each any and all of Defendants’ Released Claims against Plaintiffs’ Released Persons. Defendants shall be deemed to have, and by operation of the Judgment shall have, covenanted not to sue Plaintiffs’ Released Persons with respect to any of Defendants’ Released Claims, and shall be permanently barred and enjoined from instituting, commencing, or prosecuting any Defendants’ Released Claims against Plaintiffs’ Released Persons except to enforce the releases and other terms and conditions contained in this Stipulation and/or the Judgment entered pursuant thereto.
Why is there a Settlement?
The Court has not decided in favor of Defendants or Plaintiffs. Instead, the Parties agreed to the Settlement to avoid the distraction, costs, and risks of further litigation. The Parties also agree that the Reforms confer significant benefits to Olaplex and Olaplex’s shareholders.
Defendants have denied, and continue to deny, each and every claim and contention alleged by Plaintiffs in the Derivative Matters and affirm that they have acted properly, lawfully, and in full accord with their fiduciary duties, at all times. Further, Defendants have denied expressly, and continue to deny, all allegations of wrongdoing, fault, liability, or damage against them arising out of any of the conduct, statements, acts, or omissions alleged, or that could have been alleged, in the Derivative Matters and deny that they have ever committed or attempted to commit any violations of law, any breach of fiduciary duty owed to Olaplex or its shareholders, or any wrongdoing whatsoever. Defendants further deny that Olaplex has suffered any damage, injury, or other harm as a result of any action or inaction on their part. Had the terms of this Stipulation not been reached, Defendants assert that they would have continued to contest vigorously Plaintiffs’ allegations, and Defendants maintain that they had and have meritorious defenses to all claims alleged in the Derivative Matters. Without admitting the validity of any of the claims that Plaintiffs have asserted in the Derivative Matters, or any liability with respect thereto, Defendants have determined that it is desirable that the claims be settled on the terms and subject to the conditions set forth herein.
The Settlement Hearing and Your Right to Object to the Settlement
Any Current Olaplex Shareholder who wishes to object to the fairness, reasonableness, or adequacy of the Settlement as set forth in the Stipulation, or to the proposed award of attorneys’ fees and expenses, may file with the Court a written objection. At least twenty-one (21) days prior to the Settlement Hearing, an objector must: (1) file with the Clerk of the Court and serve upon the below listed counsel a written objection to the Settlement setting forth (a) the nature of the objection, (b) proof of ownership of Olaplex common stock as of April 24, 2026 and through the date of the Settlement Hearing (including the number of shares of Olaplex common stock held and the date of purchase), (c) any and all documentation or evidence in support of such objection, and (d) the identities of any cases, by name, court, and docket number, in which the shareholder or his, her, or its attorney has objected to a settlement in the last three years; and (2) if intending to appear and requesting to be heard at the Settlement Hearing, he, she, or it must, in addition to the requirements of (1) above, file with the Clerk of the Court and serve on the below counsel (a) a written notice of his, her, or its intention to appear at the Settlement Hearing, (b) a statement that indicates the basis for such appearance, (c) the identities of any witnesses he, she, or it intends to call at the Settlement Hearing and a statement as to the subjects of their testimony, and (d) any and all evidence that would be presented at the Settlement Hearing. Any objector who does not timely file and serve an objection in accordance with this paragraph shall be foreclosed from raising any objection to the Settlement and from objecting at the Settlement Hearing, except for good cause shown.
IF YOU MAKE A WRITTEN OBJECTION, IT MUST BE ON FILE WITH THE CLERK OF THE COURT NO LATER THAN JULY 6, 2026. The Clerk’s address is:
Clerk of the Court
United States District Court for the Central District of California
First Street United States Courthouse
350 W. First Street, 4th Floor
Los Angeles, CA 90012-2111
YOU ALSO MUST DELIVER COPIES OF THE MATERIALS TO PLAINTIFFS’ COUNSEL AND DEFENDANTS’ COUNSEL SO THEY ARE RECEIVED NO LATER THAN JULY 6, 2026. Counsel’s addresses are:
Counsel for Plaintiffs
Timothy Brown
THE BROWN LAW FIRM
767 Third Avenue, Suite 2501
New York, NY 10017
Melissa A. Fortunato
BRAGAR EAGEL & SQUIRE, P.C.
515 S. Flower Street, Suite 1800
Los Angeles, CA 90071
Seth D. Rigrodsky
RIGRODSKY LAW, P.A.
1007 North Orange Street, Suite 453
Wilmington, DE 19801
Counsel for Defendants
Anne Johnson Palmer
ROPES & GRAY LLP
One Maritime Plaza, Suite 1800
300 Clay Street
San Francisco, CA 94111
An objector may file an objection on his, her, or its own or through an attorney hired at his, her, or its own expense. If an objector hires an attorney to represent him, her, or it for the purposes of making such objection, the attorney must serve (either by hand delivery or by first class mail) a notice of appearance on the counsel listed above and file such notice with the Court no later than twenty-one (21) days before the Settlement Hearing. Any Olaplex shareholder who does not timely file and serve a written objection complying with the above terms shall be deemed to have waived, and shall be foreclosed from raising, any objection to the Settlement, and any untimely objection shall be barred.
Any objector who files and serves a timely, written objection in accordance with the instructions above, may appear at the Settlement Hearing either in person or through counsel retained at the objector’s expense. Objectors need not attend the Settlement Hearing, however, in order to have their objections considered by the Court.
If you are a Current Olaplex Shareholder and do not take steps to appear in this action and object to the proposed Settlement, you will be bound by the Judgment of the Court and will forever be barred from raising an objection to such settlement in this or any other action or proceeding, and from pursuing any of the Released Claims.
If you held Olaplex common stock as of April 24, 2026 and continue to hold such stock, you may have certain rights in connection with the proposed Settlement.
CURRENT OLAPLEX STOCKHOLDERS AS OF APRIL 24, 2026 WHO HAVE NO OBJECTION TO THE SETTLEMENT DO NOT NEED TO APPEAR AT THE SETTLEMENT HEARING OR TAKE ANY OTHER ACTION.
Interim Stay and Injunction
Pending the Court’s determination as to final approval of the Settlement, the Plaintiffs and all other Olaplex shareholders, derivatively on behalf of Olaplex, are barred and enjoined from commencing, prosecuting, instigating, continuing, or in any way participating in the commencement or prosecution of any action asserting any of Plaintiffs’ Released Claims derivatively against any of Defendants’ Released Persons.
You may obtain further information by contacting counsel for Plaintiffs at: Timothy Brown, The Brown Law Firm, 767 Third Avenue, Suite 2501, New York, NY 10017, Email: [email protected]; or Melissa A. Fortunato, Bragar, Eagel, & Squire, P.C., 515 S. Flower Street, Suite 1800, Los Angeles, CA 90071, Email: [email protected]; or Seth D. Rigrodsky, Rigrodsky Law, P.A., 1007 North Orange Street, Suite 453, Wilmington, DE 19801. Please Do Not Call the Court or Defendants with Questions About the Settlement.
Dated: May 29, 2026
BY ORDER OF THE UNITED STATES DISTRICT COURT OF THE CENTRAL DISTRICT OF CALIFORNIA
About OLAPLEX
OLAPLEX is a foundational health and beauty company powered by breakthrough innovation and the professional hairstylist. Born in the lab and brought to the chair, our products are designed to enable Pros and their clients to achieve their best results and to provide consumers with a holistic healthy hair regimen. Founded in 2014, OLAPLEX revolutionized prestige hair care with its category creating Complete Bond Technology™, which works by protecting, strengthening and relinking all three bonds during and after hair services. Since then, OLAPLEX has expanded into a full suite of hair health formulas. OLAPLEX’s award-winning products are sold globally through an omnichannel model serving the professional, specialty retail, and direct-to-consumer channels.
Contacts:
Investors:
Michael Oriolo
Vice President, Strategy & Investor Relations [email protected]
Financial Media:
Lisa Bobroff
Vice President, Global Communications & Consumer Engagement [email protected]
_____________________
i A derivative action is an action brought by a shareholder on behalf of a company, rather than on behalf of himself or herself or the other shareholders of the company. The recovery sought in a derivative action is for the benefit of the company rather than directly for individual shareholders.
ii All capitalized terms used in this Notice, unless otherwise defined below, have the same meanings used in the Stipulation.
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) has received an average rating of "Hold" from the twelve analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, four have given a buy rating and one has
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 9:30 a.m. ET. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceutical compan.
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and the nomination of Geno J. Germano as a director for election at Harmony's 2026 Annual Meeting of Shareholders. Mr. Anastasiou previously served on Harmony Biosciences' Board of Directors, where he contributed strategic insight acro.
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic growth, financial strength, and long‑term value creation. Harmony is also reiterating its 2026 net product revenue guidance of $1.0 to $1.04 billion. Mr. Reicin is a seasoned biopharmaceutical executive with extensive experience across publicly traded and pri.
Harmony Biosciences (NASDAQ:HRMY) executives outlined 2026 priorities at Needham & Company’s Virtual Healthcare Conference, emphasizing continued growth for WAKIX and multiple late-stage pipeline readouts across sleep-wake and rare epilepsy indications.
WAKIX outlook and commercial execution President and CEO Jeffrey Dayno said Harmony is “on track to achieve over $1 billion in net revenue for WAKIX in its sixth year on the market,” describing the product as the company’s foundation for near- and long-term growth.
Chief Commercial Officer Adam Zaeske pointed to accelerating patient growth exiting 2025. While the company “typically see[s] patient additions of 100-400 patients a quarter,” Zaeske said the last three quarters saw “400-500 patient adds,” which he characterized as “really, really strong growth and momentum carrying us into 2026.” He attributed the performance to WAKIX’s differentiation as “the only non-scheduled treatment option available for patients,” along with broad access and ongoing refinements to sales execution, payer coverage, and patient support processes intended to speed time to dispense.
Looking ahead, Zaeske said Harmony expanded its commercial organization in the first quarter, increasing field sales, remote sales, and field reimbursement teams “on average of about 20%,” with hires in place and trained.
ANDA litigation and loss-of-exclusivity planning Fadia asked about an outstanding abbreviated new drug application (ANDA) filer. Dayno said Harmony has “settled with six of the seven ANDA filers” with loss of exclusivity (LOE) “to September of 2029,” and he added that pediatric exclusivity—“for which we’re on track to achieve”—would extend that to “March of 2030.”
On the ongoing trial process, Dayno said post-trial briefs were submitted the prior Thursday and the company cannot “predict the timing or the outcome.” He said Harmony remains focused both on completing settlement efforts and on advancing next-generation pitolisant programs.
Pitolisant franchise: GR and high-dose programs Dayno highlighted multiple pitolisant lifecycle initiatives. He said pitolisant GR (gastroresistant) is “on track for NDA submission this quarter,” with a target PDUFA date in “the first quarter of next year of 2027.”
Zaeske said the GR formulation is intended to improve the patient experience, noting that “80% of patients with narcolepsy have the potential for GI symptoms related to the disease.” He said the GR coating “adds to” WAKIX’s tolerability foundation and also enables patients to “start at a therapeutic dose” with “no titration required.” Zaeske added that Harmony’s distribution model allows it to recontact prior WAKIX patients who consented at initiation, potentially informing patients who discontinued for various reasons that a GR formulation is available. He said Harmony has “historically…thought about the GR as between $3 million and $500 million opportunity.”
For pitolisant high dose (HD), Zaeske described the strategy as “a totally new branded launch and a highly differentiated product,” combining the GR benefits with “up to 2x the approved dose of WAKIX” and pursuing “unique indications in narcolepsy and IH.” He said the company is running two phase III registrational trials—one in narcolepsy and one in idiopathic hypersomnia (IH)—with “target PDUFA dates both in 2028,” and said Harmony has discussed HD as “a billion-plus opportunity.”
Dayno added that HD is “a unique formulation” with “a different PK profile,” stating that “milligram for milligram, greater exposure” has been demonstrated, with safety margins “well beyond going two times the highest labeled dose.” He also said the GR and HD programs are designed to support potential new labeling in areas such as “fatigue in narcolepsy” and “sleep inertia in IH,” and that the company has “utility patents out through 2044” for both GR and HD.
New pitolisant formulation targeting fatigue Dayno and Chief Medical and Scientific Officer Kumar Budur discussed an additional pitolisant formulation obtained via an exclusive license backed by an issued patent “until 2042.” Budur said Harmony’s interest in fatigue stems from its “multidimensional” nature—emotional, physical, and cognitive—and argued the histaminergic mechanism, including downstream norepinephrine and serotonin effects, is “uniquely positioned to address all three aspects of fatigue.”
Budur cited Harmony’s phase II proof-of-concept study in type 1 myotonic dystrophy, where about 90% of patients have significant fatigue, saying pitolisant improved fatigue “in a clinically meaningful way” and showed a “dose response.” He also noted pitolisant is labeled in Europe for residual excessive daytime sleepiness in obstructive sleep apnea. Based on characteristics of the newly licensed formulation, Budur said Harmony prioritized fatigue in multiple sclerosis because fatigue is “very well characterized” in MS and affects a large proportion of patients. He said the company is “optimizing the formulation” and expects the next step to be a phase I pharmacokinetic study.
Orexin program and EPX-100 in rare epilepsies Management also addressed the evolving orexin landscape and Harmony’s own orexin receptor agonist, BP1.15205. Zaeske said physicians show interest in orexins based on efficacy but still have questions about tolerability and longer-term data, citing reported adverse events such as “pretty high rates of insomnia,” frequent urination, and visual disturbances. He said Harmony expects a “gradual approach” to adoption and argued that new brands in narcolepsy historically expand branded utilization rather than solely shift share, reflecting a polypharmacy treatment paradigm. Zaeske said WAKIX’s “exceptional safety and tolerability” and “extremely clean profile” support its role as an add-on therapy.
Budur said BP1.15205 is “the most potent orexin receptor agonist in clinical development,” describing potency at “0.015 nanomolar levels,” a novel chemical scaffold intended to avoid off-target issues seen with earlier compounds, and a preclinical profile supportive of “potentially once-a-day dosing.” Dayno said Harmony expects top-line data from a phase I single-ascending-dose PK study in healthy volunteers “mid-year,” followed by an IND submission “mid-year” and a sleep-deprived healthy volunteer study to evaluate safety, tolerability, dose-ranging, and initial signals of efficacy.
In rare epilepsy, Budur discussed EPX-100, referencing open-label ARGUS data presented at AES showing a “50% median reduction” in CMS-28 from baseline. He emphasized EPX-100 is being developed as adjunctive therapy on top of multiple anti-epileptic drugs and said the program’s differentiation could include tolerability and safety, citing low rates of clinically relevant GI adverse events and no expected need for special routine monitoring such as LFT checks or echocardiograms required with other therapies. Dayno reiterated two phase III trials are advancing in Dravet syndrome and Lennox-Gastaut syndrome, with top-line data anticipated in 2027 and target PDUFA dates in 2028.
Dayno also highlighted business development as a key priority, citing “over $880 million on our balance sheet.” He said Harmony’s focus remains orphan and rare CNS and neuropsychiatric targets, but the company has “opened up the aperture” to consider broader indications adjacent to its sleep-wake and rare epilepsy franchises, including potentially “on market” assets and opportunities ranging from smaller tuck-ins to more transformational deals.
About Harmony Biosciences (NASDAQ:HRMY) Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.
The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.
See Also Five stocks we like better than Harmony Biosciences
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore open-label extension data from the company's investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2026 American Academy of Neurology Annual Meeting being held April 18 – 22 in Chicago, IL. The ARGUS trial is currently enrolling, and more information about the trial can be found at argust.
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-8461 (domestic) or 203-518-9814 (international or alternate), and reference passcode HRMYQ126. It is recommende.
Harmony Biosciences Holdings, Inc. (HRMY - Free Report) closed the last trading session at $31.83, gaining 14.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $42.91 indicates a 34.8% upside potential.
The average comprises 11 short-term price targets ranging from a low of $25.00 to a high of $72.00, with a standard deviation of $13.82. While the lowest estimate indicates a decline of 21.5% from the current price level, the most optimistic estimate points to a 126.2% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.
While the consensus price target is highly sought after by investors, the ability and unbiasedness of analysts in setting price targets have long been questionable. And investors making investment decisions solely based on this tool would arguably do themselves a disservice.
But, for HRMY, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside.
Price, Consensus and EPS Surprise
Here's What You May Not Know About Analysts' Price TargetsAccording to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading.
While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why?
They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts.
However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces.
That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism.
Here's Why There Could be Plenty of Upside Left in HRMYAnalysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For the current year, one estimate has moved higher over the last 30 days compared to no negative revision. As a result, the Zacks Consensus Estimate has increased 0.3%.
Moreover, HRMY currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Therefore, while the consensus price target may not be a reliable indicator of how much HRMY could gain, the direction of price movement it implies does appear to be a good guide.
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or argenex SE (ARGX). But which of these two stocks is more attractive to value investors?
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.
In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.
However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the traditional growth attributes to analyze a company's real growth prospects.
Harmony Biosciences Holdings, Inc. (HRMY - Free Report) is one such stock that our proprietary system currently recommends. The company not only has a favorable Growth Score, but also carries a top Zacks Rank.
Studies have shown that stocks with the best growth features consistently outperform the market. And returns are even better for stocks that possess the combination of a Growth Score of A or B and a Zacks Rank #1 (Strong Buy) or 2 (Buy).
While there are numerous reasons why the stock of this company is a great growth pick right now, we have highlighted three of the most important factors below:
Earnings GrowthEarnings growth is arguably the most important factor, as stocks exhibiting exceptionally surging profit levels tend to attract the attention of most investors. For growth investors, double-digit earnings growth is highly preferable, as it is often perceived as an indication of strong prospects (and stock price gains) for the company under consideration.
While the historical EPS growth rate for Harmony Biosciences is 12.1%, investors should actually focus on the projected growth. The company's EPS is expected to grow 23.4% this year, crushing the industry average, which calls for EPS growth of 14%.
Cash Flow GrowthWhile cash is the lifeblood of any business, higher-than-average cash flow growth is more important and beneficial for growth-oriented companies than for mature companies. That's because, growth in cash flow enables these companies to expand their businesses without depending on expensive outside funds.
Right now, year-over-year cash flow growth for Harmony Biosciences is 9%, which is higher than many of its peers. In fact, the rate compares to the industry average of 2.6%.
While investors should actually consider the current cash flow growth, it's worth taking a look at the historical rate too for putting the current reading into proper perspective. The company's annualized cash flow growth rate has been 32.4% over the past 3-5 years versus the industry average of 4.4%.
Promising Earnings Estimate RevisionsBeyond the metrics outlined above, investors should consider the trend in earnings estimate revisions. A positive trend is a plus here. Empirical research shows that there is a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
The current-year earnings estimates for Harmony Biosciences have been revising upward. The Zacks Consensus Estimate for the current year has surged 0.3% over the past month.
Bottom LineWhile the overall earnings estimate revisions have made Harmony Biosciences a Zacks Rank #2 stock, it has earned itself a Growth Score of B based on a number of factors, including the ones discussed above.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
This combination positions Harmony Biosciences well for outperformance, so growth investors may want to bet on it.
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported Q1 2026 revenue of $215.4 million, delivering 17% year‑over‑year growth for WAKIX®. Performance during the quarter reflected continued strong demand, offset by market access headwinds observed every Q1, which were more pronounced this year. This follows the strongest three consecutive quarters in franchise history, and the Company reinforced 2026 full year revenue guidance. The Company also.
Harmony Biosciences Holdings, Inc. (HRMY - Free Report) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -27.94%. A quarter ago, it was expected that this company would post earnings of $0.84 per share when it actually produced earnings of $0.38, delivering a surprise of -54.76%.
Over the last four quarters, the company has not been able to surpass consensus EPS estimates.
Harmony Biosciences, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $215.39 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 3.18%. This compares to year-ago revenues of $184.73 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Harmony Biosciences shares have lost about 12.4% since the beginning of the year versus the S&P 500's gain of 7.6%.
What's Next for Harmony Biosciences?While Harmony Biosciences has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Harmony Biosciences was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.93 on $249.23 million in revenues for the coming quarter and $3.34 on $1.03 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Prime Medicine, Inc. (PRME - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026.
This company is expected to post quarterly loss of $0.24 per share in its upcoming report, which represents a year-over-year change of +40%. The consensus EPS estimate for the quarter has been revised 0.6% higher over the last 30 days to the current level.
Prime Medicine, Inc.'s revenues are expected to be $1.56 million, up 7.6% from the year-ago quarter.
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat: June 9, 2026, at 8:40 a.m. ET Location: Miami, FL Oppenheimer CNS & Neuro-Muscular Summit Fireside Chat: June 10, 2026, at 3:25 p.m. ET Location: Miami, FL A webcast of the fireside chats will be available on the investor.
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences.
Goldman Sachs 47th Annual Global Healthcare Conference
Fireside Chat: June 9, 2026, at 8:40 a.m. ET Location: Miami, FL Oppenheimer CNS & Neuro-Muscular Summit
Fireside Chat: June 10, 2026, at 3:25 p.m. ET Location: Miami, FL A webcast of the fireside chats will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260527892644/en/
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), which will be held June 14 – 17 in Baltimore, MD. The poster presentation details are as follows: Abstract Title Poster Presentation Session Treatment with Pitolisant in Subgroups of Adults with.
